About the Phase 1 Study andFuture Development The randomized, double-blind, placebo-controlled single and multiple ascending dose study of AMG 133 enrolled people with a Body Mass Index (BMI) of ≥30.0 kg/m2 and ≤40.0 kg/m2 without other medical conditions. Participants were ran...
首先,AMG133抗体部分是GIPR的拮抗剂,抑制人源天然GIP多肽对人源GIPR受体的活性在100-130nM左右。其次,作为一个双功能分子,AMG133分子中的抗体偶联的GLP-1多肽分子经过改造,在多肽的第8位和第22位引入非天然氨基酸Aib,增加了多肽部分的血浆稳定性和半衰期,该改造GLP-1...
A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide 1 (GLP1) agonists. The researchers...
[1]Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022 . Retrieved Dec 1, 2022. From网页链接 [2]Amgen Business Review Meeting. Retrieved Fe 8, 2022, from网页链接 @药明康德内容团队报道 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代...
近日,Amgen的研究人员在Nature Metabolism期刊发表了相关研究成果[1],表明新开发的GIPR/GLP-1R双特异性分子——AMG 133,能够有效减轻雄性肥胖小鼠和食蟹猴体重并改善代谢健康。临床试验结果表明:肥胖患者只需每月一针,接受高剂量AMG 1...
AMG 133不同于单一的GLP-1受体激动剂等药物,它结合多个分子,可以同时靶控多条作用通路,不仅减重,还可以减少进食,降低热量摄入,可谓是从源头杜绝肥胖可能性。 正值春节,很多人都开起了吃吃吃模式,正所谓每逢佳节胖三斤。但是“养膘容易,减肥难”!这种对于肥胖人群而言更为痛苦:吃了长肉 OR 只能眼巴巴看着别人大...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 ...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 ...
MedChemEMaridebartcafraglutideCat.No.:HY-164535CASNo.:2887445-76-1Synonyms:AMG133作⽤靶点:GLPReceptor作⽤通路:GPCR/GProtein储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Maridebartcafraglutide⼀种抗体-肽结合物,作为GLP-1受体激动剂和...
每月1 针,仅 3 针即可减重 26 斤:安进发布「减肥针」临床数据 2月 5 日,安进(Amgen)的研究人员在 Nature Metabolism 期刊发表了题为:A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings 的研究论文,文中表示,安进开发...